Why the study?
The potential role of acute triggers on the appearance of cerebral microbleeds remains unknown.
Does transcatheter aortic valve replacement (TAVR) cause new cerebral microbleeds in patients with symptomatic aortic stenosis?
Does transcatheter aortic valve replacement (TAVR) cause new cerebral microbleeds in patients with symptomatic aortic stenosis?
New cerebral microbleeds occur in 25% of patients undergoing TAVR but do not appear to impact neurologic functional outcome or quality of life at 6 months.
Answers are grounded in this paper and cite their sources.
New post-TAVR microbleeds showed no 6-month neurologic or QoL impact; leaves open longer-term risks and need for prospective study.
BACKGROUND: Cerebral microbleeds (CMBs) have been observed in healthy elderly people undergoing systematic brain magnetic resonance imaging. The potential role of acute triggers on the appearance of CMBs remains unknown. We aimed to describe the incidence of new CMBs after transcatheter aortic valve replacement (TAVR) and to identify clinical and procedural factors associated with new CMBs including hemostatic measures and anticoagulation management. METHODS: We evaluated a prospective cohort of patients with symptomatic aortic stenosis referred for TAVR for CMBs (METHYSTROKE [Identification of Epigenetic Risk Factors for Ischemic Complication During the TAVR Procedure in the Elderly]). Standardized neurologic assessment, brain magnetic resonance imaging, and analysis of hemostatic measures including von Willebrand factor were performed before and after TAVR. Numbers and location of microbleeds on preprocedural magnetic resonance imaging and of new microbleeds on postprocedural magnetic resonance imaging were reported by 2 independent neuroradiologists blinded to clinical data. Measures associated with new microbleeds and postprocedural outcome including neurologic functional outcome at 6 months were also examined. New CMBs were not associated with changes in neurologic functional outcome or quality of life at 6 months. CONCLUSIONS: One out of 4 patients undergoing TAVR has CMBs before the procedure and 1 out of 4 patients develops new CMBs. Procedural or antithrombotic management and persistence of acquired von Willebrand factor defect were associated with the occurrence of new CMBs. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT02972008.
No takes yet. Share an insight, caveat, or question.
Belle et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: